Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care

Documenti analoghi

• Implantable cardioverter‐defibrillator lead failure and revision following transcutaneous bicaval valve (TricValve®) implantation
  di: Allan Plant, et al.
  Pubblicazione: (2024)
• Multicenter prospective observational study to clarify the current status and clinical outcome in Japanese patients who have an indication for implantable cardioverter defibrillator (ICD) or wearable cardioverter defibrillator (WCD) (TRANSITION JAPAN‐ICD/WCD study): Rationale and design of a prospective, multicenter, observational, comparative study
  di: Yukitoshi Ikeya, et al.
  Pubblicazione: (2024)
• Quality of life and acceptance of the extravascular implantable cardioverter‐defibrillator
  di: Razan Dankar, et al.
  Pubblicazione: (2024)
• How to indicate implantable cardioverter‐defibrillator in the aging population
  di: Risako Orita, et al.
  Pubblicazione: (2025)
• Long‐term safety and efficacy of subcutaneous implantable cardioverter‐defibrillator compared with transvenous implantable cardioverter‐defibrillator in propensity score‐matched patients from Japan
  di: Yuki Konno, et al.
  Pubblicazione: (2025)